Status:
RECRUITING
3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension
Lead Sponsor:
Shengjing Hospital
Conditions:
Cirrhosis
Liver Portal Hypertension
Eligibility:
All Genders
18-75 years
Brief Summary
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hyp...
Detailed Description
China suffers the heaviest burden of liver disease in the world. The number of chronic liver disease is more than 400 million. Either viral-related hepatitis, alcoholic hepatitis, or metabolic-related...
Eligibility Criteria
Inclusion
- age \> 18 years old
- confirmed cirrhosis (laboratory, imaging and clinical symptoms)
- with 3D-MRE and 2D-MRE within 1 month prior to HVPG measurement
- written informed consent
Exclusion
- any previous liver or spleen surgery
- liver cancer; chronic acute liver failure
- acute portal hypertension
- unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons
- with liver interventional therapy between HVPG and MRE
Key Trial Info
Start Date :
August 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06205992
Start Date
August 16 2022
End Date
December 1 2025
Last Update
February 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004